Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Von willebrand factor, Quantity: 1200 IU; Factor VIII, Quantity: 500 IU
CSL Behring Australia Pty Ltd
Factor VIII,Von willebrand factor
Injection, powder for
Excipient Ingredients: sucrose; trometamol; sodium chloride; Albumin; sodium citrate dihydrate; calcium chloride dihydrate
Intravenous
von Willebrand disease (VWD) - Treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A (congenital FVIII deficiency) - Prophylaxis and treatment of bleeding in patients with haemophilia A.
Visual Identification: A white or pale yellow, hygroscopic powder or friable solid; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2013-09-02